Answers are grounded in this paper and cite their sources.
Literature review demonstrates the effectiveness of PSMA theranostics in prostate cancer diagnosis and treatment, suggesting promising implications.
Summary Purpose To briefly review the current status of prostate-specific membrane antigen (PSMA) theranostics. Material and methods A literature search was conducted from 2020 to 2026 for systematic reviews addressing both diagnostic and therapeutic PSMA use in vivo in prostate cancer, excluding original works, case reports, and abstracts. Results Out of an initial 1315 results, ten systematic reviews were included. Various diagnostic PSMA radiotracers that can be labeled with gallium-68 and/or fluorine-18 exist, showing comparable results. For therapeutic applications, the widely used lutetium-177 PSMA ligands and the emerging actinium-225-labeled PSMA ligands have demonstrated prolonged progression-free survival in recent ongoing prospective trials, while no effect for overall survival could be demonstrated. Prostate-specific membrane antigen has therapeutic value beyond prostate cancer, while the role of other ligands in prostate cancer remains experimental. Conclusion The development of PSMA radiotracers has revolutionized the diagnostic approach in nuclear medicine, while their therapeutic application offers a completely novel treatment option in patients with prostate cancer.
No takes yet. Share an insight, caveat, or question.
Friedrich Weitzer (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: